It certainly appears so, based on the effects people experience from low dose Valcyte and the known of effects of microglial inhibition. I also took the standard 900 mg dose of Valcyte for five years, and the beneficial effects appear to be identical at both the high and low doses.
That's the dose required for maximum effectiveness of long term antiviral activity. However, that does not appear to be the main mode of action in people with ME/CFS. In people with AIDS, where this drug was first used, that dose was definitely necessary, as the antiviral activity was necessary, and the immunomodulatory effects were presumably negligible, as the AIDS patients didn't have much of an immune system left to modulate by the time they needed this drug. But our situation is quite different, and Dr. Montoya appears to have clearly shifted his position on the importance of the direct antiviral effects. It is my understanding that he is now saying that the 900 mg dose and possibly even lower doses may be toxic in some people, and may not even be necessary. He appears to be saying that it is not clear what dose is really necessary in ME/CFS.
As I know of only a small number of people who are trying low dose Valcyte in the amounts that I described, I know of only five people who have experienced this effect, though several (including myself) have experienced it dramatically. There are a few other people who are taking this drug at the low dose, but I have not been in regular contact with them.
Last edited:
